Active Recombinant Human EPHA2(596-900) Protein, N-His-tagged

• Cat.No.: EPHA2-66H
• Product Overview: N-terminal 6Histagged, recombinant human EphA2 residues 596–900, expressed by baculovirus in Sf21 insect cells. Purified using Ni2+/NTA-agarose.

Specification

• Description: Eph (erythropoietin-producing hepatocellular) family tyrosine kinase receptors consist of two groups: EphA group members respond to ephrin-A, which is anchored to the cell membrane by glycosylphosphatidylinositol, whereas EphB group members respond to ephrin-B, containing a transmembrane domain. High levels of EphA2 have been documented in many cell models and clinical specimens of human cancer, including metastatic melanoma and breast, prostate, lung, renal cell, colon, and esophageal carcinomas.
• Source: Sf21
• Species: Human
• Tag: His
• Protein length: 596-900 aa
• Form: 1.18mg/ml of enzyme in 50mM HEPES pH7.0, 150mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.
• Bio-activity: 268U/mg, where one unit of EphA2 activity is defined as 1nmol phosphate incorporated into 0.1mg/ml poly(Glu, Tyr) (4:1) per minute at 30 centigrade with a final ATP concentration of 100μM.
• Molecular Mass: 38 kDa
• AA Sequence: 1 MSYYHHHHHH DYDIPTTENL YFQGAMGSDP NQAVLKFTTE IHPSCVTRQK VIGAGEFGEV 61 YKGMLKTSSG KKEVPVAIKT LKAGYTEKQR VDFLGEAGIM GQFSHHNIIR LEGVISKYKP 121 MMIITEYMEN GALDKFLREK DGEFSVLQLV GMLRGIAAGM KYLANMNYVH RDLAARNILV 181 NSNLVCKVSD FGLSRVLEDD PEATYTTSGG KIPIRWTAPE AISYRKFTSA SDVWSFGIVM 241 WEVMTYGERP YWELSNHEVM KAINDGFRLP TPMDCPSAIY QLMMQCWQQE RARRPKFADI 301 VSILDKLIRA PDSLKTLADF DPRVSIRLPS TSG
• Purity: Purity 96% by SDS-PAGE and Coomassie blue staining.
• Applications: Drug Discovery & Development
• Storage: 6 months at -70 centigrade.
• Handling Advice: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into prechilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70 centigrade.
• Use/Stability: On receipt of material store at -70 centigrade. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Gene Information

• Gene Name: EPHA2 EPH receptor A2 [ Homo sapiens (human) ]
• Official Symbol: EPHA2
• Synonyms: EPHA2; EPH receptor A2; ECK; CTPA; ARCC2; CTPP1; CTRCT6
• Gene ID: 1969
• mRNA Refseq: NM_004431.5
• Protein Refseq: NP_004422.2
• MIM: 176946
• UniProt ID: P29317

Reviews

12/21/2022

The protein has low cytotoxicity.

02/03/2022

EPHA2 has good stability, and the test results of heat resistance, acid and alkali resistance and protease degradation resistance are good.

03/31/2021

Kinetic parameters such as enzymatic reaction rate and binding affinity were tested, and the protein performed well.

Q&As

What are the treatment strategies for EPHA2?

Therapeutic strategies for EPHA2 include inhibition of its expression, blocking its signal transduction pathway, and modulating its interaction with ligands. These strategies may involve the use of small molecule inhibitors, antibodies, or other types of therapeutics.

How does EPHA2 expression level relate to the occurrence and progression of the disease?

The expression level of EPHA2 is associated with the occurrence and progression of a variety of diseases. For example, in tumors such as lung, breast, and colorectal cancer, EPHA2 expression levels may be elevated and correlated with the degree of malignancy and poor prognosis of the tumor.

How does EPHA2 expression level relate to tumor prognosis?

In some tumors, EPHA2 expression levels are associated with poor prognosis in patients. For example, patients with lung cancer who express EPHA2 often have shorter survival. Therefore, the expression level of EPHA2 may be one of the indicators to predict tumor prognosis.

How can diseases be diagnosed by detecting EPHA2 expression levels?

Some diseases can be diagnosed by measuring EPHA2 expression levels, such as immunohistochemistry, western blotting, and real-time PCR.

Could EPHA2 be used as a target for the treatment of certain diseases?

Yes, EPHA2 can be used as a target for the treatment of certain diseases. For example, inhibition of EPHA2 expression can inhibit tumor growth and spread, so EPHA2 can serve as a potential therapeutic target. In addition, regulating the expression level of EPHA2 may also be helpful in the treatment of diseases such as the nervous system and cardiovascular system.

What is the role of EPHA2 in cancer metastasis?

EPHA2 can promote cancer metastasis and affect the spread and spread of cancer by regulating processes such as invasion and migration of tumor cells. Therefore, inhibition of EPHA2 expression or blocking its signal transduction pathway may have a potential therapeutic effect on inhibiting cancer metastasis.